GSKGLAXF
13F holders, Q2 2026 (June 30)2holders
0new positions
0sold out
$26.29avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding GSK PLC (GLAXF) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holders were Aristotle Capital Management, LLC ($69.3M) and Generali Investments CEE, investicni spolecnost, a.s. ($896K).
- Company
- GSK PLC
- CUSIP
- G3910J179
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 195,016 shares sold, net −195,016 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Aristotle Capital Management, LLC | 0.15% | Reduce -6.8% | 2,633,914 | $69.3M |
| Generali Investments CEE, investicni spolecnost, a.s. | 0.04% | Reduce -11.0% | 34,105 | $896K |
"% of holder's portfolio" is GLAXF's weight in each manager's 13F, not the share of GSK PLC the manager owns.